Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models

Neoplasia

Volumn 7, Issue 2, 2005, Pages 152-161

  Ulivi, Paola ^a   Zoli, Wainer ^a   Fabbri, Francesco ^a   Brigliadori, Giovanni ^a   Ricotti, Luca ^a   Tesei, Anna ^a   Rosetti, Marco ^a   De Cesare, Michelandrea ^b   Beretta, Giovanni L ^b   Corna, Elisabetta ^b   Supino, Rosanna ^b   Zunino, Franco ^b  

^a ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor activity; Bladder carcinoma; Camptothecins; DNA topoisomerase I; Gimatecan

Indexed keywords

BORTEZOMIB; CAMPTOTHECIN DERIVATIVE; DNA; DNA TOPOISOMERASE; ENZYME; GIMATECAN; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; TERT BUTOXYIMINOMETHYLCAMPTOTHECIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL CYCLE S PHASE; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIZATION; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 20044367822     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04397     Document Type: Article

References (22)

1. Zunino F and Pratesi G (2004). Camptothecins in clinical development. Exp Opin Invest Drugs 13, 269-284.
2. Pizzolato JF and Saltz LB (2003). The camptothecins. Lancet 361, 2235-2242.
3. Zunino F, Dallavalle S, Laccabue D, Beretta GL, Merlini L, Pratesi G (2003). Current status and perspectives in the development of camptothecins. Curr Pharm Des 8, 2505-2520.
4. Thomas CJ, Rahier NJ, and Hecht SM (2004). Camptothecin: current perspectives. Bioorg Med Chem 12, 1585-1604.
5. Pommier Y, Pourquier P, Fan Y, and Strumberg D (1998). Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400, 83-106.
6. Liu LF, Desai SD, Li TK, Mao Y, Sun M, and Sim SP (2000). Mechanism of action of camptothecin. In Liehr JG, Giovanella BC, Verschraegen CF (Eds.), The Camptothecins. Unfolding Their Anticancer Potential (Vol. 922, pp. 1-10 New York Academy of Sciences).
7. Darzynkiewicz Z, Bruno S, Del Bino G, and Traganos F (1996). The cells cycle effects of camptothecin. In Pantazis P, Giovanella BC, Rothenberg ML (Eds.), The Camptothecins. From Discovery to the Patients (Vol. 803, 93-110 New York Academy of Sciences).
8. Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Penco S, Carminati C, et al. (2002). Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 8, 3904-3909.
9. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82, 1107-1112.
10. Drewinko B, Loo TL, Brown JA, Gottlieb JA, and Freireich EJ (1976). Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combination on cultured human lymphoma cells. Cancer Biochem Biophys 1, 187-195.
11. De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, et al. (2001). Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61, 7189-7195.
12. Desai SD, Li T-K, Rodriguez-Bauman A, Rubin EH, and Liu LF (2001). Ubiquitin/26S proteasome - mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61, 5926-5932.
13. Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, et al. (2003). Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol 65, 1281-1294.
14. Bertrand R, O'Connor PM, Kerrigan D, and Pommier Y (1992). Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma Ht-29 cells. Eur J Cancer 28, 743-748.
15. Miele L (2003). Regulation of cell cycle and apoptosis. In Giordano A, Soprano KJ (Eds.), Cancer Drug Discovery and Development: Cell Cycle Inhibitors in Cancer Therapy: Current Strategies, (pp. 83-118, Humana Press Inc., Totowa, NJ).
16. Pratesi G, Beretta GL, Zunino F, and Gimatecan F (2004). A novel camptothecin with a promising preclinical profile. Anticancer Drugs 15, 545-552.
17. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, et al. (2001). A novel 7 - modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61, 6034-6037.
18. Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, and Zunino F (2004). Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol 67, 1035-1045.
19. Dallavalle S, Ferrari A, Biasotti B, Merlini L, Penco S, Gallo G, Marzi M, Tinti MO, Martinelli R, Pisano C, et al. (2001). Novel 7 - oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 44, 3264-3274.
20. Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T, and Kuwano M (1996). Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res 56, 2348-2354.
21. Desai SD, Zhang H, Rodriguez-Bauman A, Yang JM, Wu X, Gounde MK, Rubin EH, and Liu LF (2003). Transcription-dependent degradation of topoisomerase I - DNA covalent complexes. Mol Cell Biol 23, 2341-2350.
22. Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, and Zunino F (2003). Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 1, 863-870.